XERS Stock Price, Xeris Pharmaceuticals Quote, Chart

Market Summary

USD1.98-0.04

Market Closed

-1.98%

XERS Alerts

1 major insider buys recently.

Losses in recent quarter

XERS Stock Price

View Fullscreen

XERS RSI Chart

XERS Valuation

Market Cap

293.5M

Price/Earnings (Trailing)

-4.56

Price/Sales (Trailing)

1.71

Price/Free Cashflow

-7.13

XERS Price/Sales (Trailing)

XERS Profitability

Return on Equity

701.69%

Return on Assets

-19.13%

Free Cashflow Yield

-14.03%

XERS Fundamentals

XERS Revenue

Revenue (TTM)

171.4M

Rev. Growth (Yr)

22.42%

Rev. Growth (Qtr)

-8.45%

XERS Earnings

Earnings (TTM)

-64.4M

Earnings Growth (Yr)

-12.75%

Earnings Growth (Qtr)

-41.75%

Breaking Down XERS Revenue

Last 7 days

12.5%

Last 30 days

11.2%

Last 90 days

-38.5%

Trailing 12 Months

-29.5%

How does XERS drawdown profile look like?

XERS Financial Health

Current Ratio

2.37

Debt/Equity

-25.02

Debt/Cashflow

-0.18

XERS Investor Care

Shares Dilution (1Y)

7.97%

Diluted EPS (TTM)

-0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	171.4M	0	0	0
2023	121.4M	134.1M	152.7M	163.9M
2022	63.5M	79.9M	98.5M	110.2M
2021	27.7M	35.0M	42.3M	49.6M
2020	0	0	0	20.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Xeris Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 10, 2024	schmid john p.	bought	10,314	1.91	5,400	-
Mar 18, 2024	johnson john	acquired	429,044	1.99	215,600	-
Mar 15, 2024	kong garheng	acquired	-	-	6,474	-
Mar 15, 2024	johnson john	acquired	-	-	89,571	-
Mar 15, 2024	sherman jeffrey w	acquired	-	-	6,502	-
Mar 14, 2024	schmid john p.	bought	9,720	2.16	4,500	-
Jan 31, 2024	edick paul r	acquired	-	-	1,500,000	see remarks
Jan 31, 2024	johnson kenneth erland	acquired	-	-	175,000	see remarks
Jan 31, 2024	pieper steven	acquired	-	-	450,000	see remarks
Jan 31, 2024	hecht beth	acquired	-	-	750,000	see remarks

Which funds bought or sold XERS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-21,900	29,570	-%
May 16, 2024	JANE STREET GROUP, LLC	added	2.85	-17,215	508,207	-%
May 16, 2024	COMERICA BANK	new	-	922	922	-%
May 15, 2024	Alpine Global Management, LLC	added	11.11	28,500	663,000	0.17%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-33,135	-	-%
May 15, 2024	MPM BIOIMPACT LLC	added	8.3	166,961	9,207,960	1.48%
May 15, 2024	Redmile Group, LLC	unchanged	-	-146,522	2,312,960	0.09%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-39,630	-	-%
May 15, 2024	NEA Management Company, LLC	new	-	926,211	926,211	0.06%
May 15, 2024	Asset Management Group, Inc.	unchanged	-	-1,607	25,371	-%

Are Funds Buying or Selling XERS?

Are funds buying XERS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XERS

No. of Funds

Unveiling Xeris Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	stonepine capital management, llc	4.3%	5,937,000	SC 13G/A
Feb 13, 2024	vanguard group inc	5.13%	7,086,345	SC 13G
Jan 26, 2024	blackrock inc.	7.2%	10,011,391	SC 13G
Feb 14, 2023	caxton corp	4.4%	5,973,324	SC 13G/A
Feb 13, 2023	stonepine capital management, llc	8.2%	11,195,189	SC 13G/A
Feb 10, 2023	blackrock inc.	6.3%	8,576,213	SC 13G
Feb 11, 2022	flynn james e	2.05%	2,614,379	SC 13G/A
Jul 12, 2021	blackrock inc.	2.5%	1,684,166	SC 13G
Mar 17, 2021	flynn james e	985%	5,526,709	SC 13G
Feb 16, 2021	redmile group, llc	4.9%	2,397,441	SC 13G/A

Recent SEC filings of Xeris Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 23, 2024	DEFA14A	DEFA14A
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	ARS	ARS
Apr 11, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to Xeris Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Xeris Pharmaceuticals Inc News

Latest updates

Xeris Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-8.5%	41.00	44.00	48.00	38.00	33.00	33.00	30.00	25.00	22.00	21.00	11.00	9.00	8.00	9.00	9.00
Operating Expenses	1.2%	55.00	54.00	53.00	54.00	46.00	48.00	49.00	44.00	51.00	70.00	35.00	35.00	25.00	-	20.00
S&GA Expenses	2.2%	38.00	38.00	37.00	38.00	34.00	34.00	34.00	33.00	36.00	54.00	27.00	26.00	19.00	-	16.00
R&D Expenses	22.5%	8.00	6.00	5.00	6.00	5.00	5.00	6.00	4.00	6.00	10.00	6.00	5.00	4.00	-	4.00
Interest Expenses	-0.3%	7.00	7.00	7.00	7.00	6.00	4.00	4.00	3.00	4.00	2.00	2.00	2.00	2.00	-	2.00
Income Taxes	230.1%	0.00	-0.24	-0.34	-0.67	-	-0.34	-0.34	-0.34	-0.41	-	-	-	-	-	-
Net Income	-41.7%	-18.98	-13.39	-12.19	-19.84	-16.83	-12.93	-21.83	-26.18	-33.71	-50.79	-26.01	-27.51	-18.41	-21.86	-16.00
Net Income Margin	1.0%	-0.38*	-0.38*	-0.40*	-0.53*	-0.64*	-0.86*	-1.34*	-1.71*	-2.17*	-2.47*	-2.22*	-2.39*	-2.90*	-4.46*	-
Free Cashflow	-371.8%	-20.30	7.00	-14.74	-13.87	-26.27	-16.25	-17.89	-20.74	-48.54	-29.08	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	4.3%	337	323	328	329	321	345	303	319	338	304	131	159
Current Assets	10.9%	173	156	158	156	166	187	149	161	178	143	124	152
Cash Equivalents	-0.8%	67.00	67.00	46.00	46.00	51.00	122	84.00	95.00	104	67.00	59.00	38.00
Inventory	5.3%	41.00	39.00	38.00	37.00	29.00	25.00	20.00	18.00	17.00	18.00	14.00	8.00
Net PPE	-3.1%	6.00	6.00	6.00	7.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00
Goodwill	0%	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	-
Liabilities	5.0%	346	329	324	315	291	299	248	245	241	209	134	125
Current Liabilities	-23.2%	73.00	95.00	87.00	80.00	81.00	74.00	69.00	65.00	66.00	79.00	37.00	28.00
Long Term Debt	20.3%	230	191	190	188	188	187	139	138	138	88.00	88.00	87.00
Shareholder's Equity	-35.3%	-9.18	-6.78	4.00	14.00	30.00	45.00	55.00	74.00	96.00	95.00	-	34.00
Retained Earnings	-3.1%	-636	-617	-603	-591	-571	-554	-541	-520	-493	-460	-409	-337
Additional Paid-In Capital	2.7%	627	610	608	605	602	600	597	594	590	555	407	371
Shares Outstanding	7.3%	148	138	138	138	137	136	136	135	135	125	66.00	-
Float	-	-	-	-	362	-	-	-	209	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-371.8%	-20,303	7,471	-14,610	-13,744	-26,140	-16,119	-17,754	-20,609	-48,409	-28,946	-22,611	-20,022	-23,956	-	-
Share Based Compensation	36.1%	3,767	2,767	2,457	2,928	2,564	2,766	2,941	3,152	3,301	2,743	3,665	2,512	2,461	-	-
Cashflow From Investing	-232.2%	-19,650	14,868	14,655	8,452	-43,979	9,168	6,709	11,868	6,716	36,602	18,505	16,556	26,301	-	-
Cashflow From Financing	2952.0%	35,194	-1,234	-72.00	556	-863	49,156	-187	310	78,194	125	1.00	460	26,661	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XERS Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 40,638	$ 33,196
Costs and expenses:
Cost of goods sold	5,971	5,319
Research and development	7,821	4,838
Selling, general and administrative	38,380	33,605
Amortization of intangible assets	2,711	2,711
Total costs and expenses	54,883	46,473
Loss from operations	(14,245)	(13,277)
Other income (expense):
Interest and other income	1,923	1,300
Debt refinancing costs	(2,690)	0
Interest expense	(7,032)	(6,216)
Change in fair value of warrants	4	0
Change in fair value of contingent value rights	3,367	1,359
Total other expense	(4,428)	(3,557)
Net loss before benefit from income taxes	(18,673)	(16,834)
Income tax (expense) benefit	(307)	0
Net loss	(18,980)	(16,834)
Other comprehensive loss, net of tax:
Unrealized losses on investments	(10)	(6)
Foreign currency translation adjustments	(1)	0
Comprehensive loss	$ (18,991)	$ (16,840)
Net loss per common share - basic (in dollars per share)	$ (0.14)	$ (0.12)
Net loss per common share - Diluted (in dollars per share)	$ (0.14)	$ (0.12)
Weighted average common shares outstanding - basic (in shares)	140,513,907	137,142,565
Weighted average common shares outstanding - Diluted (in shares)	140,513,907	137,142,565
Product revenue, net
Total revenue	$ 40,263	$ 32,265
Royalty, contract and other revenue
Total revenue	$ 375	$ 931

XERS Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 62,690	$ 67,449
Short-term investments	24,662	5,002
Trade accounts receivable, net	37,414	39,197
Inventory	40,878	38,838
Prepaid expenses and other current assets	7,636	5,778
Total current assets	173,280	156,264
Property and equipment, net	5,783	5,971
Operating lease right-of-use assets	23,027	23,204
Goodwill	22,859	22,859
Other assets	107,053	109,764
Other assets	4,614	4,540
Total assets	336,616	322,602
Current Liabilities
Accounts payable	7,094	11,565
Current operating lease liabilities	4,624	3,495
Other accrued liabilities	22,391	23,510
Accrued trade discounts and rebates	22,560	22,149
Accrued returns reserve	14,593	14,198
Current portion of contingent value rights	1,021	19,109
Other current liabilities	801	1,167
Total current liabilities	73,084	95,193
Long-term debt, net of unamortized debt issuance costs	229,674	190,932
Non-current operating lease liabilities	34,397	34,764
Non-current contingent value rights	0	1,379
Deferred tax liabilities	2,575	2,268
Other liabilities	6,064	4,848
Total liabilities	345,794	329,384
Commitments and contingencies (Note 14)
Stockholders' Equity
Preferred stock—par value $0.0001, 25,000,000 shares and 25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Common stock—par value $0.0001, 350,000,000 shares and 350,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 148,224,403 and 138,130,715 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	15	14
Additional paid in capital	626,848	610,254
Accumulated deficit	(636,005)	(617,025)
Accumulated other comprehensive loss	(36)	(25)
Total stockholders’ equity (deficit)	(9,178)	(6,782)
Total liabilities and stockholders’ equity (deficit)	$ 336,616	$ 322,602

About Xeris Pharmaceuticals Inc

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

CEO	Mr. Paul R. Edick
WEBSITE	xerispharma.com
INDUSTRY	Biotechnology
EMPLOYEES	355

Xeris Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Xeris Pharmaceuticals Inc? What does XERS stand for in stocks?

XERS is the stock ticker symbol of Xeris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xeris Pharmaceuticals Inc (XERS)?

As of Fri May 17 2024, market cap of Xeris Pharmaceuticals Inc is 293.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XERS stock?

You can check XERS's fair value in chart for subscribers.

What is the fair value of XERS stock?

You can check XERS's fair value in chart for subscribers. The fair value of Xeris Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xeris Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XERS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xeris Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XERS is over valued or under valued. Whether Xeris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Xeris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XERS.

What is Xeris Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, XERS's PE ratio (Price to Earnings) is -4.56 and Price to Sales (PS) ratio is 1.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XERS PE ratio will change depending on the future growth rate expectations of investors.